A new partnership between Concept Life Sciences and OpenBench aims to revolutionize the early stages of drug discovery for biotech firms by leveraging artificial intelligence to streamline hit validation processes.
The collaboration combines OpenBench’s AI-driven structure-based platform with Concept Life Sciences’ expertise in medicinal chemistry and validation services. This integrated approach is designed to expedite the transition from target identification to validated hit series in just six months, significantly reducing both time and upfront research costs.
In this model, OpenBench performs virtual screenings of extensive compound libraries and synthesizes selected candidate molecules, which are then tested and validated by Concept Life Sciences. Notably, OpenBench will finance the initial discovery phase and implement a fee-for-success structure, meaning clients only incur costs when validated hits are delivered. This innovative approach minimizes the financial risks typically associated with early drug discovery.
The partnership is particularly timely as many biotech companies are grappling with funding challenges. By offering a more capital-efficient alternative to conventional discovery methods, this collaboration aims to provide biotech firms with validated chemical leads while reducing early-stage R&D risks. As Steven L. Holshouser from Concept Life Sciences noted, this model addresses the urgent need for faster and lower-risk paths to quality chemical starting points in today's funding climate.